Long non-coding RNAs (lncRNAs) are a class of endogenous noncoding RNAs of more than 200 nucleotides and have no capability to encode the functional proteins. But, increasing evidence shows that they act a role in gene expression and regulation, RNA processing and translation in human diseases including cancer. 4, 5 NEAT1 as a nuclear-restricted lncRNA was thought to promote myeloid differentiation in acute promyelocytic leukaemia 6 and androgen receptor-associated prostate cancer progression. 7 Subsequently, NEAT is responsible for reducing chemotherapy sensitivity 8, 9 and accelerating tumorigenesis in breast cancer, 10 ovarian cancer 11 and bladder cancer, 12 acting as a potential prognostic predictor of glioma. 13 Accumulating data indicate that lncRNAs act as competing endogenous RNAs (ceRNAs) to reduce the activity of microRNAs (miRNAs) through shared miRNA response elements (MREs) in cancer. 14, 15 For example, NEAT1 facilitates tumour progression in lung cancer, 16 and laryngeal squamous cell carcinoma by miR-107/CDK6 axis 17 and in pancreatic cancer by miR-335/c-met axis, 18 and contributes to the chemo-resistance to gemcitabine in cholangiocarcinoma. 19 These studies unveil the key regulation crosstalk between NEAT1 and miRNAs in cancer.
Although NEAT1 was previously reported to serve as a marker for CRC, 20 the functions of NEAT1 in CRC are still unknown. In this study, we found that NEAT1 expression was upregulated in CRC samples and was associated with TNM stage and poor prognosis, acting as an independent prognostic factor of tumour recurrence in patients with CRC. Moreover, NEAT1 promoted the tumorigenesis of CRC cells by sponging miR-193a and represented a potential marker for CRC patients.
| MATERIAL S AND ME THODS

| Materials
CRC cell lines (LOVO, HCT116, DLD-1, Caco2 and SW480) and normal tissues used in our study were from Liver Cancer Institute of Zhongshan Hospital. Lentivirus-mediated sh-NEAT1 or negative control (NC) vectors, virion-packaging elements, miR-193a mimic and inhibitor were purchased from Genechem (Shanghai, China); The antibodies against E-cadherin (24E10, rabbit monoclonal antibody), N-cadherin (#4061, rabbit polyclonal antibody), Vimentin (D21H3, rabbit monoclonal antibody) and PCNA (#13110, rabbit monoclonal antibody) were from Cell Signaling Technologies (Beverly, MA, USA) and anti-IL17RD (PA5-21682, rabbit polyclonal antibody) was from Thermo Fisher Scientific (Waltham, MA, USA). The TCGA RNA sequencing data of CRC patients were downloaded from the website (https://xenabrowser.net/heatmap/) and summarized in Table S1 . 
| Drugs and reagents
| Plasmid construction
We commercially synthesized the miR-193a inhibitor and mimic (100 nmol/L), and the wild type NEAT1 vector, which contained the miR-193a binding sites, and the mutant fragment, which contained the mutant binding sites of miR-193s, were obtained by annealing double-strand DNA and inserted into the pmirGLO vector at the BamHI and EcoRI sites. The full-length NEAT1 (accession number: NR_028272) was amplified with the following primers:
forward, 5′CTTCCTCCCTTTAACTTATCCATTCAC-3′; reverse, 5′-CTCTTCCTCCACCAT TACCAACAATAC-3′. Then, it was cloned into the EcoRI and MluI sites of the pCMV-GFP vector. The sh-NEAT1
plasmid, expressing a siRNA that targets NEAT1 transcription, was constructed by annealing single-strand hairpin cDNA and the detailed description referred to the reference. 
| Cell culture and lentiviral transfection
CRC cells were cultured in DMEM medium supplemented with 10% heat-inactivated FBS, 100 U/mL of penicillin and 100 μg/mL of streptomycin. Cells in this medium were placed in a humidified atmosphere containing 5% CO2 at 37°C. When cells reached 60% confluence, they were transfected with recombinant experimental virus or control virus, and cultured at 37°C and 5% CO2 for 4 hours.
Then supernatant was discarded and serum containing growth medium was added. Positive and stable transfectants were selected and expanded for further study.
| Quantitative Real-time PCR (qRT-PCR)
To quantitatively confirm the mRNA expression levels of NEAT1 in CRC cell lines and tissues, real-time PCR was performed. Total RNA was extracted from each clone using TRIzol according to the manufacturer's protocol. Reverse transcription was carried out using M-MLV and cDNA amplification was performed using the SYBR Green Master
Mix kit according to the manufacturer's guidelines. GAPDH or U6 gene was used as an endogenous control. A miScript Primer Assay (QIAGEN) was used for the miR-193a and U6. Data were analysed using the comparative Ct method (2− △△Ct ). Three separate experiments were performed for each clone. The primers used were listed in Table S2 .
| Western blot analysis
CRC cell lines were harvested and extracted using lysis buffer (TrisHCl, SDS, Mercaptoethanol, Glycerol). Cell extracts were boiled for 5 minutes in loading buffer, and then, equal amount of cell extracts were separated on 12% SDS-PAGE gels. Separated protein bands were transferred into polyvinylidene fluoride (PVDF) membranes. under 5% CO2 for 10 days.
| Cell viability assay
| Cell invasion and apoptosis assays
Cell transwell assay and flow cytometry analysis were conducted for assessing the cell invasive potential and apoptotic index as previously reported. Reporter System (Promega).
| Animal experiments
Six-week-old female immune-deficient nude mice (BALB/c-nu) were bred at the laboratory animal facility. All experimental procedures were performed according to the regulations and internal biosafety and bioethics guidelines of Zhongshan Hospital, Fudan University.
Mice were injected subcutaneously with 5 × 10 6 LOVO CRC cells.
Mice were monitored daily and developed a subcutaneous tumour.
The tumour volume every three days was measured with a calliper using the formula: volume = (length × width)2/2. The expression levels of lncRNA NEAT1 and miR-193a were detected between sh-NEAT1 group and sh-NC group by qRT-PCR analysis.
| Statistical analysis
SPSS 18.0 (IBM, SPSS, Chicago, IL, USA) was used for the statistical analysis. All of the values were recorded as the Mean ± SEM from at least three independent experiments. Two-tailed Student's t test was used to evaluate the differences between each group. The cutoff value of NEAT1 was determined by the NEAT1 expression level, survival time and survival status (the number of death n = 94 or survivors n = 298) and it was used to distinguish the NEAT1 high expression (n = 60) or low expression level (n = 332), by which survival curves were plotted using the Kaplan-Meier method and were assessed for the statistical significance using a log-rank test. Statistical significance was set at P < 0.05.
| RE SULTS
| LncRNA NEAT1 expression was upregulated in human CRC samples
Some studies have shown that lncRNA NEAT1 expression is increased in some cancers. [10] [11] [12] [13] To verify the expression of NEAT1 in CRC tissues, we used 2015 TCGA sequencing data (https://genomecancer.ucsc.edu/), which showed that NEAT1 expression was significantly upregulated in unpaired (n = 392) or paired CRC samples (n = 27) as compared to the normal tissues (n = 27) ( Figure 1A ). In addition, NEAT1 expression was elevated in CRC with T3+T4 stage (n = 318) as compared to those with T1+T2 stage (n = 74) or normal tissues (n = 27) ( Figure 1B ).
| LncRNA NEAT1 expression was correlated with poor survival and recurrence in patients with CRC
We further analysed the correlation of NEAT1 expression with the clinicopathological features and prognosis in patients with CRC. Based on the NEAT1 expression level, overall survival (OS) time and survival status, we obtained a suitable cut-off value of NEAT1 in 392 CRC patients ( Figure S1A ) using the cut-off finder (https://molpath.
charite.de/cutoff/load.jsp), among which NEAT1 was divided into high expression group and low expression group ( Figure 1C ). As shown in Table 1 , NEAT1 high expression was positively associated with TNM stage (P = 0.024), but had no correlation with age, gender, tumour localization, pathological stage and lymphatic invasion of the patients (each P > 0.05). We then drew the survival and recurrence curves, which showed that the CRC patients with NEAT1 high expression had shorter survival and higher tumour recurrence as compared to those with NEAT1 low expression ( Figure 1D) . Moreover, the patients of early stage or late stage with NEAT1 high expression had the shorter survival ( Figure 1E ), but had no difference in tumour recurrence as compared to those with NEAT low expression ( Figure S1B ).
In addition, univariate cox regression analysis revealed that NEAT1 high expression was related with an increased risk of the survival (RR 1.299, 95% CI 0.974 to 1.500; P = 0.025) and recurrence of CRC (RR 1.246, 95% CI 1.001 to 1.550; P = 0.042) (Tables S3 and S4) .
Considering all the potential confounding factors, multivariate Cox regression analysis showed that NEAT1 expression was an independent predictor of tumour recurrence (Table S4) in patients with CRC. Figure 2C ), but ectopic expression of NEAT1 displayed a proliferation promoting effect in SW480 cells ( Figure 2D ).
In addition, the number of colony formation in sh-NEAT1 transfected LOVO and HCT116 cell lines was significantly reduced as compared to empty vector ( Figure 2E ), but NEAT1 overexpression increased the colony formation number in SW480 cell line ( Figure 2F ). Interestingly, we also assessed the effects of NEAT1 
| LncRNA NEAT1 promoted CRC cell invasion
To observe the effects of NEAT1 on CRC cell invasion, we conducted a transwell invasion assay, which showed that knockdown of NEAT1 weakened cell invasive potential in LOVO and HCT116 cell lines, but overexpression of NEAT1 promoted these effects in SW480
cell line ( Figure 3A) . The protein expression of epithelial-mesenchymal transition (EMT) markers, such as E-cadherin, N-cadherin and 
| LncRNA NEAT1 acted as a sponge of miR-193a in CRC cells
To uncover the molecular mechanism by which NEAT1 contributes to CRC, using the bioinformatics analysis software starBase v2.0 (https://starbase.sysu.edu.cn/targetSite.php), according to the very high stringency (>5) and its expression in more than three tumour styles, 23 miRNAs were identified to bind with NEAT1 (Table S5) .
Meanwhile, using miRcode (https://www.mircode.org/index.php), eight miRNAs were found to interact with NEAT1 (Table S6) Previous studies have shown that miRNAs act as miRNA ribonucleoprotein complexes including Ago2, an important component of RNAinduced silencing complex (RISC). 21 Given that Ago2 generally interacts with RNAs in the cytoplasm, we then conducted a RIP assay using antiAgo2 antibody. Both NEAT1 and miR-193a were enriched by five to -sixfold following immunoprecipitation using the anti-Ago2 antibody as compared to anti-IgG in LOVO and HCT116 cell lines ( Figure 4G ).
| NEAT1 knockdown counteracted miR-193a inhibitor-induced tumour promoting effects in CRC cells
We inhibitor ( Figure 5A,B) . Previous studies showed that IL17RD was a direct target of miR-193a in CRC cells. 22 We also identified IL17RD
as a key target of miR-193a according to the cumulative weighted context score (−0.95) using the TargetScan (https://www.targetscan.
org/vert_71/) (Table S7 ). TCGA data showed that IL17RD expression was markedly upregulated in CRC ( Figure 5C ) and had the negative correlation with miR-193a expression in CRC ( Figure 5D ). To uncover the direct relationship between NEAT1 and IL17RD, we transfected the shNEAT1 into LOVO and HCT116 CRC cell lines and NEAT1 over- effects of co-transfection of miR-193a inhibitor and sh-NEAT1 on the expression of IL1RD by qRT-PCR ( Figure 5F ) and Western blot assays ( Figure 5G ), which demonstrated that miR-193a inhibitor increased the expression of IL17RD but knockdown of NEAT1 attenuated this increased effect induced by miR-193a inhibitor.
| Knockdown of NEAT1 inhibited xenograft tumour growth
Having investigated the tumour promoting effects of NEAT1 on CRC cells in vitro, we further checked its effect in vivo. A subcutaneous LOVO xenograft model was established to observe the tumour growth activity affected by NEAT1 knockdown. During the tumour growth period, the growth activity of xenograft tumour was measured. We found that the proliferation rates of tumours were lowered by NEAT1 knockdown (Figure 6A,B) . When the tumours were harvested, the average volumes and weight in sh-NEAT1 group were decreased compared with sh-NC group (Figure 6C,D) .
Then, we extracted the RNA and protein from the tumour tissues derived from the sh-NEAT1 and sh-NC groups, and detected the expression levels of NEAT1 and miR-193a by qRT-PCR and that of PCNA by Western blot analysis, which indicated that NEAT1 expression was decreased ( Figure 6E ), but miR-193a expression was increased ( Figure 6F ) in sh-NEAT1 group as compared to sh-NC, and knockdown of NEAT1 downregulated the expression of PCNA in tumour tissues compared with the sh-NC group ( Figure 6G ).
| D ISCUSS I ON
LncRNA NEAT1 is implicated in diverse biological processes and acts as a potential predictor for survival and recurrence in CRC, gastric cancer (GC) 23 and oesophageal squamous cell carcinoma. 24 Herein, we found that NEAT1 was upregulated in CRC, and associated with tumour stage, overall survival and recurrence, acting as an independent prognostic factor for tumour recurrence in patients with CRC. Our findings corroborated the previous studies in CRC 20 and GC. 23 These studies suggest that NEAT1 might act as a potential biomarker in CRC. 
29
NEAT1 also sponges miR-449b-5p/c-Met axis to promote glioma pathogenesis. 26 In this study, we confirmed miR-193a-specific It is known that miR-193a acts as a potential tumour suppressor in malignant tumours. 30 On the one hand, it inhibits tumour metastasis in osteosarcoma by targeting Rab27B and SRR 31 with the previous study, 22 we here found that miR-193a was downregulated in CRC samples and had the negative correlation with IL17RD expression, which has been confirmed as a direct target of miR-193a in CRC. 22 Then, miR-193a inhibitor increased proliferation and invasion and upregulated IL17RD expression in CRC cells, and these tumour promoting effects induced by miR-193a inhibitor were counteracted by NEAT1 knockdown. NEAT1 also upregulated the expression of IL17RD, but knockdown of NEAT1 downregulated its expression. Our results inferred that NEAT1 might act as a sponge of miR-193a to reduce its activity, and increase IL17RD expression, resulting in CRC tumorigenesis. (Figure 6H ).
| CON CLUS IONS
In conclusion, our findings demonstrated that lncRNA NEAT1 promoted CRC progression via sponging miR-193a and was associated with poor survival and recurrence of CRC patients. Our study might provide an intriguing biomarker for CRC patients.
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